Andrew G. Franks

Biosketch / Results /

Andrew G. Franks, M.D.

Clinical Professor; Dir Connective Tissue Disease Service
Ronald O. Perelman Department of Dermatology (Fac) and Medicine (Rheum Div)
NYU Dermatologic Associates

Clinical Addresses

NEW YORK, NY 10016
Handicap Access: yes
Phone: 212-263-5015

« Back to Results

Medical Specialties

Dermatology, Internal Medicine, Rheumatology

Medical Expertise

Scleroderma, Lupus of the Skin, Connective Tissue Disease

Clinical Responsibilities

Andrew G. Franks, Jr., M.D., FACP is one of a few physicians in the United States who hold board certification in Dermatology, Rheumatology, and Internal Medicine. Over the past forty years he has earned a distinct reputation in the area of skin manifestations of autoimmune disease with particular emphasis on lupus erythematosus, scleroderma, morphea, dermatomyositis, Raynaud's syndrome and related disorders. In addition, he has been a team medical consultant for the New York Yankees (1978-2001), New York Knicks (1978-2001), New York Jets (1978-1989), New York Rangers (1980-1987), and New Jersey Blue Devils (1982-2009) with particular emphasis on sports related injury. He was an original member of the Association of Professional Team Physicians with special expertise in sports related knee injury, and in 1986 was an inaugural rheumatologist at the Hospital for Joint Disease when it affiliated with NYU. He is regarded as a leading clinical expert in both distinct fields by his peers and has published numerous scientific articles and textbook chapters and has lectured extensively during the course of his career on both cutaneous as well as rheumatologic disorders. Dr. Franks is a Clinical Professor of Dermatology & Medicine (Rheumatology) and the Director of the Skin Lupus & Autoimmune Connective Tissue Disease Service at New York University Medical Center and continues to train other dermatologists, rheumatologists, and students in both specialties. He has received numerous honors including the NYU Alpha Omega Alpha Distinguished Clinical Teaching Award, and is also listed repeatedly in Best Doctors in America by Castle Connelly and New York Magazine for over 15 consecutive years. He is a Diplomate of the American Boards of Dermatology, Internal Medicine and Rheumatology, and is a Fellow of the American College of Physicians, American College of Rheumatology, and the American Academy of Dermatology. He is also a Founding Fellow of the American Rheumatism Association.

Principal Investigator, Clinical Trials Unit

« Back to Results

Board Certification

1975 — Ab Internal Medicine - Internal Medicine
1977 — Ab Dermatology - Dermatology
1978 — Ab Internal Medicine (Rheumatology)


1971 — New York Medical College, Medical Education
1971-1972 — New York Medical College, Internship
1972-1973 — New York Medical College, Residency Training
1973-1974 — Beth Israel Medical Center, Residency Training
1974-1975 — Columbia Presbyterian Medical Center, Residency Training
1975-1976 — Columbia Presbyterian Medical Center, Clinical Fellowships
1975-1977 — Columbia Presbyterian Medical Center, Clinical Fellowships

« Back to Results

Research Summary

Dr. Franks' initial research in autoimmune disease began in 1979 with a publication in the Journal of Investigative Dermatology on the effects of fibrinogen degradation products on lymphocytes, particularly in systemic lupus erythematosus. This was performed under the mentorship of Dr. Dorothy Estes, in the laboratory of Dr. Jane Morse at both Rockefeller University and Columbia Presbyterian Medical Center. In 1982. working under Dr. E. Carwile Leroy at The Scleroderma Center at Columbia Presbyterian he published in The Lancet on the appropriate use of topical nitroglycerin for the treatment of Raynaud's phenomenon and digital ulcers, receiving international recognition and an Exceptional Research Award presented at the University of Hamburg. He has recently added another innovative treatment and published his research (2012) in the "Cutting Edge" section of the Archives of Dermatology on the use of Botolinum toxin for treatment of aggressive secondary Raynaud's in patients with scleroderma and other autoimmune disease. He was an early advocate (1980's) of the use of azathioprine in recalcitrant cutaneous lupus erythematosus and published his research in both the Archives of Dermatology as well as the Journal of the American Academy of Dermatology. His interest in novel treatments for cutaneous lupus erythematosus has recently led to his introduction of a human monoclonal antibody directed against interleukin 12 and interleukin 23 for the treatment of resistant lupus including subacute cutaneous lupus (SCLE), published in the "Cutting Edge" section of The Archives of Dermatology (2011). This was followed by the introduction and publication in The Journal of Drugs in Dermatology (2012) of the first successful trial of the novel oral small molecule apremilast to be utilized in the treatment of cutaneous lupus erythematosus. He also participated in the early outcome assessment of belimumab a human monoclonal antibody that inhibits BAFF(BlyS), a breakthrough treatment for systemic lupus erythematosus (Arthritis & Rheumatism (2012). In the late seventies, working with Dr. Richard Edelson at Columbia Presbyterian Medical Center, he became knowledgable in the use of photopheresis for T-Cell lymphoma. He then collaborated on the use of extracorporeal photopheresis in the treatment of fibrosis in Scleroderma. This research led to one of the first papers on its positive benefit and was published in 1993 in The International Journal of Dermatology. He has recently re-entered fibrosis research and has collaborated with Drs. Bruce Cronstein and Edwin Chan in the NYU Translational Research Department on the effects of the pro-fibrotic cytokines IL-33 and IL-13 and how they modulate dermal fibrosis via the A2A adenosine receptor. This work has been published (2012, 2013) in The Journal of Investigative Dermatology, The Journal of the American Academy of Dermatology, and Arthritis and Rheumatism. As a co-Principal Investigator with the Research Division of the NYU Department of Radiology, he is also currently involved in an innovative, breakthrough study to determine therapeutic outcomes in patients with Amyopathic Dermatomyositis utilizing NYU Research Radiology's revolutionary diffusion MRI.

Research Interests

Lupus Erythematosus, Scleroderma/Morphea, Dermatomyositis Raynaud's Phenomenon

Research Documents